Therapixel and Onsite Women's Health Partner to Deploy AI for Breast Cancer Detection

Therapixel has announced a strategic partnership with Onsite Women's Health to deploy its MammoScreen AI technology across more than 150 locations, announced in a press release. This collaboration aims to enhance breast cancer detection by providing radiologists with AI-driven insights, improving diagnostic accuracy and efficiency.

MammoScreen uses deep learning to identify subtle abnormalities that might be missed during manual reviews. It has shown the capability to detect 42% of cancers a year before diagnosis and 38.5% two years prior. By integrating this technology, Onsite Women's Health aims to improve patient outcomes by offering faster and more accurate readings.

The partnership will allow Onsite Women's Health to leverage MammoScreen's capabilities to reduce reader fatigue and inter-reader variability, thereby increasing consistency in patient care. Additionally, the technology's increased specificity is expected to lower unnecessary recalls, minimizing patient anxiety and inconvenience.